Brii BiosciencesFRA:7SS -18.03%33 PB Ratio is 0.25 as of Jun. 24, 2026, which is 36% below its 10-year median of 0.39. GuruFocus rates FRA:7SS with a GF Score™ of 33/100. The stock has 1 warning sign investors should review. Among 1,233 Biotechnology companies, Brii Biosciences ranks better than 97.4% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-24), Brii Biosciences's share price is €0.10. Brii Biosciences's Book Value per Share for the quarter that ended in Dec. 2025 was €0.40. Hence, Brii Biosciences's PB Ratio of today is 0.25.
Good Sign:
Brii Biosciences Ltd stock PB Ratio (=0.28) is close to 1-year low of 0.28.
The historical rank and industry rank for Brii Biosciences's PB Ratio or its related term are showing as below:
FRA:7SS'
s PB Ratio Range Over the Past 10 Years
Min: 0.18 Med: 0.39 Max: 2.75
Current: 0.28
During the past 7 years, Brii Biosciences's highest PB Ratio was 2.75. The lowest was 0.18. And the median was 0.39.
FRA:7SS's PB Ratio is ranked better than 97.4% of 1233
companies
in the Biotechnology industry
Industry Median: 2.83
vs FRA:7SS: 0.28
During the past 12 months, Brii Biosciences's average Book Value Per Share Growth Rate was -6.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -9.50% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Brii Biosciences was -9.50% per year. The lowest was -12.00% per year. And the median was -10.75% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Brii Biosciences PB Ratio Related Terms
Brii Biosciences PB Ratio Historical Data
* Premium members only.
The historical data trend for Brii Biosciences's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Brii Biosciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Brii Biosciences PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Brii Biosciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where Brii Biosciences's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Brii Biosciences (FRA:7SS) has a PB Ratio of 0.25 as of Jun. 24, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Brii Biosciences and its competitors. This is 36% below median its historical median of 0.39. Over the past decade, Brii Biosciences' PB Ratio has ranged from 0.18 to 2.75. According to the industry distribution chart, Brii Biosciences ranks #32 out of 1233 companies in the Biotechnology industry, placing it in the top 2.6%.
Is Brii Biosciences' PB Ratio too high?
Brii Biosciences' current PB Ratio of 0.25 is 36% below median its 10-year median of 0.39. Over the past 10 years, this metric has ranged from a low of 0.18 to a high of 2.75. The Biotechnology industry median PB Ratio is 2.83. Brii Biosciences' value of 0.25 is 91.2% below this industry median. Based on the distribution chart, Brii Biosciences ranks #32 out of 1233 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Brii Biosciences has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Brii Biosciences' PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Brii Biosciences ranks #32 out of 1233 companies for PB Ratio. This places Brii Biosciences in the top 3% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.83. Brii Biosciences' value of 0.25 is 91.2% below this benchmark. Historically, Brii Biosciences' own PB Ratio has ranged from 0.18 to 2.75 over the past decade. While the company's 10-year median is 0.39 vs. the industry median of 2.83, Brii Biosciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.83, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Brii Biosciences's current PB Ratio of 0.25 is 91.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Brii Biosciences and its competitors. For the Biotechnology industry, the median PB Ratio is 2.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Brii Biosciences's current PB Ratio is 0.25, which is 36% below median its own 10-year median of 0.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brii Biosciences stock overvalued right now?
Brii Biosciences (FRA:7SS) has a current PB Ratio of 0.25. The current PB Ratio is 0.25, which is 36% below median its 10-year median of 0.39 and 91.2% below the Biotechnology industry median of 2.83. Brii Biosciences' overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Brii Biosciences (FRA:7SS), the current PB Ratio is 0.25 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
AddressNo. 1 North Yongtaizhuang Road, 3rd Floor, Building 7, Zhongguancun Dongsheng, International Science Park, Haidian District, Beijing, CHN, 100192
Brii Biosciences Ltd is a biotechnology company based in China and the United States. It is committed to developing advancing therapies for infectious diseases, such as HBV, HIV, MDR/XDR gram-negative infections, and other illnesses, such as CNS diseases, which have public health burdens in China and around the world. The company's pipeline of products includes more than 10 product candidates that focus on infectious diseases and mental illnesses.
33GF Score
Get the complete analysis for FRA:7SS
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7SS has been successfully added to your 
